EUVIMEDEUVIMED entdecken
Vergleichsstudie

Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study

Masaki Hatano, Yusuke Sasabuchi, Akira Okada, Yuya Kimura, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga

Annals of the Rheumatic Diseases · 2025-11 · 84 (11) · 1938-1947

DOI: 10.1016/j.ard.2025.06.2124 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2025-11. Verfasst von Masaki Hatano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Electronic address: h-masak…. Hauptthemen laut MEDLINE: Teriparatide, Osteoporosis, Bone Density Conservation Agents, Osteoarthritis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To compare osteoarthritis among individuals with osteoporosis initiating romosozumab vs an active comparator. METHODS: This new user comparative effectiveness study, emulating a target trial, included individuals aged ≥50 years in the administrative claims database from 2019 to 2022. Individuals who initiated romosozumab were compared with those who initiated teriparatide. The primary outcome was the incidence of osteoarthritis, while secondary outcomes included joint-specific osteoarthritis (knee, hip, and hand) at 1 year. Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics between romosozumab and teriparatide users, and inverse probability of censoring weighting (IPCW) was employed to account for informative censoring. Absolute risk reduction (ARR) and relative risk (RR) at 1 year were estimated using a weighted Kaplan-Meier estimator. RESULTS: A total of 22,145 individuals were included in the study (87% female; mean age, 80 years). After IPTW-IPCW adjustment, romosozumab was associated with a lower risk of osteoarthritis compared with teriparatide (ARR, 1.1% [95% CI, 0.5%-1.8%]; RR, 0.79 [0.66, 0.89]). Joint-specific analyses showed the following results: knee osteoarthritis: ARR, 0.8% (95% CI, 0.3%-1.5%), RR, 0.79 (0.66, 0.92); hip osteoarthritis: ARR, 0.2% (95% CI, 0.0%-0.5%), RR, 0.68 (0.37, 1.05); and hand osteoarthritis: ARR, 0.2% (95% CI, 0.0%-0.4%), RR, 0.61 (0.35, 1.06). CONCLUSIONS: Romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. Similar trends were observed for hip and hand osteoarthritis; however, the differences were not significant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeriparatideOsteoporosisBone Density Conservation AgentsOsteoarthritisAntibodies, MonoclonalHumansFemaleAgedMaleMiddle AgedAged, 80 and overIncidenceOsteoarthritis, Hip

Substanzen

TeriparatideromosozumabBone Density Conservation AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Electronic address: h-masaki@g.ecc.u-tokyo.ac.jp.
  • Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Hatano, M., Sasabuchi, Y., Okada, A., Kimura, Y., Ishikura, H., Tanaka, T., Saito, T., Tanaka, S., & Yasunaga, H. (2025). Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study. Annals of the Rheumatic Diseases, 84(11), 1938-1947. https://doi.org/10.1016/j.ard.2025.06.2124

Vancouver

Hatano M, Sasabuchi Y, Okada A, Kimura Y, Ishikura H, Tanaka T, et al. Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study. Annals of the Rheumatic Diseases. 2025;84(11):1938-1947. doi:10.1016/j.ard.2025.06.2124

BibTeX
@article{Hatano2025,
  author = {Hatano, Masaki and Sasabuchi, Yusuke and Okada, Akira and Kimura, Yuya and Ishikura, Hisatoshi and Tanaka, Takeyuki and Saito, Taku and Tanaka, Sakae and Yasunaga, Hideo},
  title = {Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  volume = {84},
  number = {11},
  pages = {1938--1947},
  doi = {10.1016/j.ard.2025.06.2124}
}
Kostenlos starten →